[Targeting KRAS pathway in NSCLC therapy]

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• KRAS mutations are the most frequent oncogenic drivers in non-small cell lung cancer (NSCLC).
• Targeting RAS signaling pathways represents a key therapeutic strategy for NSCLC.
• Previous attempts targeting farnesyltransferases yielded limited success.

Purpose of the Study:

• To review the therapeutic strategies targeting RAS in NSCLC.
• To evaluate the potential of targeting RAF and MEK pathways as an alternative approach.

Main Methods:

• Review of current literature on KRAS mutations and targeted therapies in NSCLC.
• Analysis of clinical trial data for farnesyltransferase inhibitors.
• Evaluation of preclinical and clinical evidence for RAF and MEK inhibitors in NSCLC.

Main Results:

• Direct targeting of RAS protein via farnesyltransferase inhibitors has shown limited efficacy in early clinical trials.
• Targeting downstream effectors, specifically RAF and MEK kinases, presents a more promising therapeutic avenue.
• Emerging data suggests RAF/MEK inhibition could offer a viable treatment option for NSCLC patients with KRAS mutations.

Conclusions:

• Targeting RAF and MEK pathways is a potentially more effective strategy for NSCLC with KRAS mutations compared to direct RAS inhibition.
• Further clinical investigation into RAF and MEK inhibitors is warranted for NSCLC treatment.